Skip to content
Open access

Predicting SILENT after lithium poisoning: a multicenter cohort study and pragmatic risk stratification model.

Sep 2026 · Clinical toxicology · pp. 1-10 · 0 citations · 17 references
Medicine

TL;DR

SILENT is not an exceptional outcome after lithium poisoning and cannot be predicted by serum lithium alone, but a simple clinical prediction model may identify patients warranting structured neurological follow-up.

Abstract

INTRODUCTION The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) is a rare but potentially devastating complication of lithium poisoning. Current evidence rests on case reports and small series, leaving its true incidence, risk factors, and follow-up tools poorly defined.

Methods

Retrospective, international, multicenter cohort of adults evaluated for lithium poisoning (2015-2022) across 23 tertiary hospitals in Spain, Ireland, and Switzerland. SILENT was defined as persistent neurological sequelae attributed to lithium toxicity documented at 60 days. A parsimonious multivariable logistic regression model was built from routinely available clinical variables and assessed by ROC analysis and internal split-sample validation.

Results

Among 644 episodes, SILENT was identified in 49 (7.6%); predicted probabilities were available for 456 episodes (39 SILENT cases). Affected patients were older and more often had acute-on-chronic poisoning, early neurological manifestations, and greater clinical severity. Serum lithium concentrations were not associated with SILENT. The model-age, poisoning type, neurological findings (ataxia/myoclonus), Poisoning Severity Score, and peak urea-showed good discrimination (AUC 0.813; 95% CI 0.743-0.882) and acceptable internal validation (AUC 0.730; 95% CI 0.572-0.888). A sensitivity-oriented threshold (P≥0.0475) yielded a high negative predictive value (98.2%), supporting its use to prioritize post-discharge neurological follow-up.

Discussion

SILENT occurred more frequently than case-based literature suggests and followed a recognizable presentation pattern. Serum lithium alone did not predict long-term sequelae. The model, based on routine variables, may offer a pragmatic tool for early risk stratification.

Conclusion

SILENT is not an exceptional outcome after lithium poisoning and cannot be predicted by serum lithium alone. A simple clinical prediction model may identify patients warranting structured neurological follow-up. External validation is required before implementation.

Read PDF

Similar papers

Open access Sep 2026

Clinical context enhances interpretation of extracorporeal treatment criteria in lithium poisoning

Lithium poisoning presents as acute, acute-on-chronic, or chronic exposure, phenotypes that differ in clinical expression and outcome. The Extracorporeal Treatments in Poisoning Workgroup criteria guide extracorporeal treatment, but whether their prognostic performance varies by poisoning type is uncertain. We as...

Álvaro Pineda-Torcuato, A. Caballero-Bermejo, August Supervía et al. · 0 citations
Open access Sep 2026

Association of lithium versus valproate initiation with all-cause mortality and incident dementia: a multinational real-world cohort study

Background Lithium and valproate are widely prescribed mood stabilizers, but their comparative long-term associations with mortality and dementia remain uncertain. We compared the risks of all-cause mortality and incident dementia among adults initiating lithium or valproate using a large multinational electronic healt...

Da-Han Hou, Yu-Hsien Wu, Ming-Ju Wu et al. · 0 citations
Open access Sep 2026

Pharmacological management in frontotemporal dementia and patient outcomes: a retrospective cohort study using the TriNetX platform

Symptomatic treatment remains the cornerstone of therapeutic management in frontotemporal dementia (FTD), as disease-modifying therapies are currently unavailable. However, several medications originally developed for other neuropsychiatric conditions may represent potentially harmful medications (PHMs) in FTD. This st...

L. Botton, F. J. Lazzaretti, Carlos Lokschin et al. · 0 citations
Review Open access Sep 2026

Impact of Medication-Related Problems in Hospitalized Patients Eligible for Palliative Care: A Prospective Cohort Study.

BACKGROUND Hospitalized patients receiving palliative care frequently present multimorbidity and polypharmacy, increasing exposure to adverse drug events (ADEs). Evidence specific to this population, particularly in middle-income countries, remains scarce. METHODS Prospective observational cohort study conducted from...

Jéssica Gonçalves Rangel, Maria Fernanda Carvalho Ribeiro, A. Maure et al. · 0 citations
Open access Sep 2026

Statin use and risk of remote seizure after first new onset status epilepticus.

OBJECTIVE Preclinical evidence supports the role of statins as antiepileptogenic agents. In this study, we investigated the risk of remote unprovoked seizures (RS) according to the use of statin therapy in a cohort of first-ever status epilepticus (SE) survivors. METHODS Retrospective analysis was made of adult patie...

Niccolò Orlandi, G. Giovannini, Lisa Taruffi et al. · 0 citations
Open access Oct 2026

Association of extracorporeal therapy with persistent neurologic sequelae after lithium poisoning: A multicentre cohort study.

AIMS Lithium poisoning may result in persistent neurologic sequelae, including irreversible neurotoxicity. Although extracorporeal therapy enhances lithium elimination, its effect on clinically meaningful outcomes remains uncertain. We evaluated the association between extracorporeal therapy and persistent neurologic s...

A. Shabaka, Eugenia Landaluce-Triska, Maria José Ortega Fernández-Reyes et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.